Article
Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
International journal of dermatology - 1 Sept 2019
Mauzo Shakuntala H, Tetzlaff Michael T, Nelson Kelly, Amaria Rodabe, Patel Sapna, Aung Phyu P, Nagarajan Priyadharsini, Torres-Cabala Carlos A, Diab Adi, Prieto Victor G, Curry Jonathan L
Abstract excerpt
BACKGROUND: Immune checkpoint antibody blockade is an emerging therapeutic option for treating certain cancers including melanoma. This therapy is associated with dermatologic and systemic toxicities, some of which are more severe than others and may require withholding therapy. CASE REPORTS: We report two patients with melanocytic nevi that regressed with pembrolizumab therapy. The first patient had stage IV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.